Kopran Ltd's subsidiary receives approval from USFDA for supply of API Atenolol

Kopran Limited has announced that the Active Pharmaceutical Ingredients Manufacturing facility at Mahad of Kopran Research Laboratories Limited, a 100 percent subsidiary of the company was inspected by the USFDA in January 2019 without any observation under Para 483.

The Company had filed the DMF of Atenolol which has now been approved by the USFDA and the Company can commence supplies of the API Atenolol to the US market.

Shares of KOPRAN LTD. was last trading in BSE at Rs.37.15 as compared to the previous close of Rs. 35.9. The total number of shares traded during the day was 135733 in over 1178 trades.

The stock hit an intraday high of Rs. 38 and intraday low of 33.45. The net turnover during the day was Rs. 4926358.

Source : Equity Bulls

Keywords